Introduction: The post-COVID condition (PCC) is defined by the World Health Organization (WHO) as the persistence or emergence of symptoms after SARS-CoV-2 infection. Acute COVID-19 is associated with a hyperinflammatory state, especially in severe cases. However, few studies addressed the profile of plasma extracellular vesicles (EVs) in the post COVID-19 period. This study aimed to evaluate leukocyte- and platelet-derived EVs and immune mediators in individuals with PCC. Methods: A cross-sectional observational study was performed with patients diagnosed with SARS-CoV-2 during 2020-2022 (IRB 59213722.5.0000.5243). Samples were collected during the acute phase and in the post-COVID period and patients were stratified according to PCC diagnose (WHO) and to hospitalization during the acute infection. Blood samples were collected in 3.2% sodium citrate and serum-separating tubes and centrifuged (2,000 xg 10 min 25ºC) to obtain plasma and serum, respectively. Total plasma EVs and leukocyte- and platelet-derived EVs were isolated by differential centrifugation (12,000xg 2 min, 20,0000xg 20 min at 4ºC). EVs were identified by size (100-900 nm – Gigamix) and positivity for Annexin V and anti-human CD45 (leukocyte marker) or CD41 (platelet marker) and quantified by nanoscale flow cytometry (CytoFLEX S, Beckman Coulter). Negative controls during acquisition, solutions of 0.1% Triton-X, Milli-Q water, Isotype, Annexin V buffer and antibody mixture were used. Circulant levels of cytokines, chemokines and growth factors were assessed by a multiplex assay. Results: We included 46 participants (mean age 54±14 years and 69.6% of females), 23 with PCC (50%). In comparison to the acute phase, counts of total and platelet-derived EVs were significantly decreased in the post-COVID period, independently of PCC diagnosis or previous hospitalization (p<0.0001), but leukocyte-derived EVs count were unchanged. Regarding immune mediators, we observed that levels of IL-6, IFN-gamma, IL-1 Ra, IL-13, MCP-1, IL-8 and MIP-1-alpha were also reduced in the post-COVID period compared to the acute phase. Despite that no differences were found when plasma EVs were compared between PCC and non-PCC groups, we found higher levels of IL-1Ra in the PCC group (p<0.0001). In addition, we found that the levels of IL-1Ra and IFN-gamma are correlated to total and platelet EVs in the PCC group. Conclusions: Our results suggest platelet-derived EVs and circulant levels of immune mediators do not remain increased in the post-COVID period, despite the need for hospitalization in the acute phase or the symptoms reported in the post-COVID period.